Optimi Health Gains Broader Australian Market Access After TGA Revises Authorized Prescriber Framework

Cross-border supply of Schedule I-equivalent substances into a regulated commercial market just became more viable: Optimi Health Corp. stands to see increased demand from its GMP-compliant Canadian facility after Australia's Therapeutic Goods Administration published final recommendations expanding the Authorized Prescriber scheme for psilocybin and MDMA on May 29, 2026.

The updated framework introduces three operationally significant changes. Therapy team composition is broadened, the dosing room's second practitioner may now be drawn from psychotherapists, counsellors, social workers, and Aboriginal and Torres Strait Islander health workers, provided the AP psychiatrist determines competency and an HREC provides oversight. Treatment settings are no longer confined to day hospital or inpatient environments; any medically supervised site meeting defined safety standards qualifies, provided it maintains Schedule 8 secure storage, resuscitation-capable staff, rescue medications, and a location within 15 minutes of an accredited emergency department. The AP psychiatrist must remain physically on-site during administration and conduct real-time patient screening and informed consent.

For manufacturers tracking this market, the regulatory architecture is worth examining closely. Australia remains the only jurisdiction to have formally scheduled both psilocybin and MDMA as medicines, for treatment-resistant depression and PTSD respectively, and the AP scheme now enters its third year of commercial operation with no serious adverse events reported under the program. The TGA's willingness to revise prescriber and setting requirements based on stakeholder consultation, which closed May 19, 2026, signals an iterative regulatory posture that differs materially from static scheduling frameworks elsewhere.

Optimi's supply position depends on continued cross-border movement of controlled substances from Canada into Australia, a pathway that requires sustained GMP compliance and alignment with both 21 CFR Part 211-equivalent Canadian standards and TGA import requirements. The workforce expansion, supported by Mind Medicine Australia's Certificate in Psychedelic-Assisted Therapy, which has trained more than 750 clinicians under Australian Medical CPD Standards, directly affects the patient volume Optimi's production output must be sized to meet.

The TGA's framework revision also carries implications for manufacturers in other jurisdictions monitoring Australia as a regulatory reference point; the setting and workforce changes demonstrate that post-approval scheme modifications can occur through targeted consultation rather than full rescheduling review.

Patient volume under the AP scheme will be the measurable indicator of whether the workforce and setting expansions translate into the demand increase Optimi's production planning now anticipates.

Source: GlobeNewswire via IBN, May 29, 2026.